These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

232 related items for PubMed ID: 15033359

  • 1. Crystal structure of HEL4, a soluble, refoldable human V(H) single domain with a germ-line scaffold.
    Jespers L, Schon O, James LC, Veprintsev D, Winter G.
    J Mol Biol; 2004 Apr 02; 337(4):893-903. PubMed ID: 15033359
    [Abstract] [Full Text] [Related]

  • 2. The influence of the framework core residues on the biophysical properties of immunoglobulin heavy chain variable domains.
    Honegger A, Malebranche AD, Röthlisberger D, Plückthun A.
    Protein Eng Des Sel; 2009 Mar 02; 22(3):121-34. PubMed ID: 19136675
    [Abstract] [Full Text] [Related]

  • 3. Energy-based analysis and prediction of the orientation between light- and heavy-chain antibody variable domains.
    Narayanan A, Sellers BD, Jacobson MP.
    J Mol Biol; 2009 May 22; 388(5):941-53. PubMed ID: 19324053
    [Abstract] [Full Text] [Related]

  • 4. Improving solubility and refolding efficiency of human V(H)s by a novel mutational approach.
    Tanha J, Nguyen TD, Ng A, Ryan S, Ni F, Mackenzie R.
    Protein Eng Des Sel; 2006 Nov 22; 19(11):503-9. PubMed ID: 16971398
    [Abstract] [Full Text] [Related]

  • 5. Structure of a non-camelized human M12-V(H) domain at 1.5A resolution.
    Gaur RK.
    J Struct Biol; 2005 Oct 22; 152(1):84-9. PubMed ID: 16183303
    [Abstract] [Full Text] [Related]

  • 6. Conserved amino acid networks involved in antibody variable domain interactions.
    Wang N, Smith WF, Miller BR, Aivazian D, Lugovskoy AA, Reff ME, Glaser SM, Croner LJ, Demarest SJ.
    Proteins; 2009 Jul 22; 76(1):99-114. PubMed ID: 19089973
    [Abstract] [Full Text] [Related]

  • 7. The importance of framework residues H6, H7 and H10 in antibody heavy chains: experimental evidence for a new structural subclassification of antibody V(H) domains.
    Jung S, Spinelli S, Schimmele B, Honegger A, Pugliese L, Cambillau C, Plückthun A.
    J Mol Biol; 2001 Jun 08; 309(3):701-16. PubMed ID: 11397090
    [Abstract] [Full Text] [Related]

  • 8. Solution structure and backbone dynamics of an antigen-free heavy chain variable domain (VHH) from Llama.
    Renisio JG, Pérez J, Czisch M, Guenneugues M, Bornet O, Frenken L, Cambillau C, Darbon H.
    Proteins; 2002 Jun 01; 47(4):546-55. PubMed ID: 12001233
    [Abstract] [Full Text] [Related]

  • 9. Aggregation-resistant VHs selected by in vitro evolution tend to have disulfide-bonded loops and acidic isoelectric points.
    Arbabi-Ghahroudi M, To R, Gaudette N, Hirama T, Ding W, MacKenzie R, Tanha J.
    Protein Eng Des Sel; 2009 Feb 01; 22(2):59-66. PubMed ID: 19033278
    [Abstract] [Full Text] [Related]

  • 10. Arginine mutation alters binding of a human monoclonal antibody to antigens linked to systemic lupus erythematosus and the antiphospholipid syndrome.
    Lambrianides A, Giles I, Ioannou Y, Mason L, Latchman DS, Manson JJ, Isenberg DA, Rahman A.
    Arthritis Rheum; 2007 Jul 01; 56(7):2392-401. PubMed ID: 17599767
    [Abstract] [Full Text] [Related]

  • 11. Rearrangement of the former VL interface in the solution structure of a camelised, single antibody VH domain.
    Riechmann L.
    J Mol Biol; 1996 Jun 28; 259(5):957-69. PubMed ID: 8683598
    [Abstract] [Full Text] [Related]

  • 12. Structure-based improvement of the biophysical properties of immunoglobulin VH domains with a generalizable approach.
    Ewert S, Honegger A, Plückthun A.
    Biochemistry; 2003 Feb 18; 42(6):1517-28. PubMed ID: 12578364
    [Abstract] [Full Text] [Related]

  • 13. Humanization of a highly stable single-chain antibody by structure-based antigen-binding site grafting.
    Villani ME, Morea V, Consalvi V, Chiaraluce R, Desiderio A, Benvenuto E, Donini M.
    Mol Immunol; 2008 May 18; 45(9):2474-85. PubMed ID: 18313757
    [Abstract] [Full Text] [Related]

  • 14. Analysis of the horse V(H) repertoire and comparison with the human IGHV germline genes, and sheep, cattle and pig V(H) sequences.
    Almagro JC, Martinez L, Smith SL, Alagon A, Estevez J, Paniagua J.
    Mol Immunol; 2006 Apr 18; 43(11):1836-45. PubMed ID: 16337682
    [Abstract] [Full Text] [Related]

  • 15. The role of interface framework residues in determining antibody V(H)/V(L) interaction strength and antigen-binding affinity.
    Masuda K, Sakamoto K, Kojima M, Aburatani T, Ueda T, Ueda H.
    FEBS J; 2006 May 18; 273(10):2184-94. PubMed ID: 16649995
    [Abstract] [Full Text] [Related]

  • 16. Crystal structure of a shark single-domain antibody V region in complex with lysozyme.
    Stanfield RL, Dooley H, Flajnik MF, Wilson IA.
    Science; 2004 Sep 17; 305(5691):1770-3. PubMed ID: 15319492
    [Abstract] [Full Text] [Related]

  • 17. Intrabody construction and expression III: engineering hyperstable V(H) domains.
    Wirtz P, Steipe B.
    Protein Sci; 1999 Nov 17; 8(11):2245-50. PubMed ID: 10595527
    [Abstract] [Full Text] [Related]

  • 18. Structural consequences of humanizing an antibody.
    Holmes MA, Foote J.
    J Immunol; 1997 Mar 01; 158(5):2192-201. PubMed ID: 9036965
    [Abstract] [Full Text] [Related]

  • 19. A peptide mimic of an antigenic loop of alpha-human chorionic gonadotropin hormone: solution structure and interaction with a llama V(HH) domain.
    Ferrat G, Renisio JG, Morelli X, Slootstra J, Meloen R, Cambillau C, Darbon H.
    Biochem J; 2002 Sep 01; 366(Pt 2):415-22. PubMed ID: 11996668
    [Abstract] [Full Text] [Related]

  • 20. Stabilization and humanization of a single-chain Fv antibody fragment specific for human lymphocyte antigen CD19 by designed point mutations and CDR-grafting onto a human framework.
    Kügler M, Stein C, Schwenkert M, Saul D, Vockentanz L, Huber T, Wetzel SK, Scholz O, Plückthun A, Honegger A, Fey GH.
    Protein Eng Des Sel; 2009 Mar 01; 22(3):135-47. PubMed ID: 19188138
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.